Key facts
- Dexlevo’s last known valuation is $233.4M (Nov 2021).
- It has raised $69.3M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Smilegate Investment, Shinhan Capital, Small and Medium Business Corporation, Magna Investment (Seoul), SB Partners (South Korea) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Dexlevo
- ·The full record, as it builds
Funding rounds
No funding rounds for Dexlevo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dexlevo
Developer of medical aesthetic products intended to enhance skin health through polymer technology. The company's platform features biodegradable polymers that promote collagen formation and support skin regeneration, enabling healthcare professionals to provide minimally invasive treatments for patients seeking skin rejuvenation.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2013
- Employees
- 96
- Website
- dexlevo.co.kr/
- Ownership
- Privately Held (backing)
Dexlevo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dexlevo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dexlevo in its N-PORT filings yet. We sweep new filings monthly.